• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Rituximab in minimal change disease and focal segmental glomerulosclerosis.

作者信息

Kronbichler Andreas, Gauckler Philipp, Bruchfeld Annette

机构信息

Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, Innsbruck, Austria.

Department of Clinical Sciences Interventions and Technology (CLINTEC), Division of Renal Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

出版信息

Nephrol Dial Transplant. 2021 May 27;36(6):983-985. doi: 10.1093/ndt/gfz205.

DOI:10.1093/ndt/gfz205
PMID:31580445
Abstract
摘要

相似文献

1
Rituximab in minimal change disease and focal segmental glomerulosclerosis.利妥昔单抗治疗微小病变肾病和局灶节段性肾小球硬化症
Nephrol Dial Transplant. 2021 May 27;36(6):983-985. doi: 10.1093/ndt/gfz205.
2
Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?利妥昔单抗在成人微小病变性肾病和局灶节段性肾小球硬化症中的应用：已知和未知的有哪些？
Autoimmun Rev. 2020 Nov;19(11):102671. doi: 10.1016/j.autrev.2020.102671. Epub 2020 Sep 15.
3
Rituximab in adult minimal change disease and focal segmental glomerulosclerosis.利妥昔单抗治疗成人微小病变病和局灶节段性肾小球硬化症
Nephron Clin Pract. 2014;128(3-4):277-82. doi: 10.1159/000368590. Epub 2014 Nov 8.
4
Rituximab as a Preemptive Treatment to Prevent Recurrence of Primary Focal Segmental Glomerulosclerosis: A Novel Approach.利妥昔单抗作为预防原发性局灶节段性肾小球硬化复发的抢先治疗：一种新方法。
Exp Clin Transplant. 2019 Jun;17(3):326-329. doi: 10.6002/ect.2018.0027. Epub 2019 Mar 14.
5
A case of recurrent focal segmental glomerulosclerosis after kidney transplantation associated with variant conversion in the Columbia classification.1例肾移植后复发性局灶节段性肾小球硬化症伴哥伦比亚分类中的变异转换
Nephrology (Carlton). 2015 Jul;20 Suppl 2:96-100. doi: 10.1111/nep.12457.
6
Successful treatment of adult-onset collapsing focal segmental glomerulosclerosis with rituximab.利妥昔单抗成功治疗成人起病的塌陷型局灶节段性肾小球硬化症。
Clin Kidney J. 2013 Oct;6(5):500-2. doi: 10.1093/ckj/sft102. Epub 2013 Sep 5.
7
Histopathological atlas of renal diseases: Minimal Change disease and focal glomerulosclerosis.肾脏疾病组织病理学图谱：微小病变病和局灶节段性肾小球硬化症
J Nephrol. 2005 Jan-Feb;18(1):1-4.
8
Recurrent Focal Segmental Glomerulosclerosis and Abatacept: Case Report.复发性局灶节段性肾小球硬化症与阿巴西普：病例报告
Exp Clin Transplant. 2016 Aug;14(4):456-9. doi: 10.6002/ect.2014.0154. Epub 2014 Nov 27.
9
High-Dose Rituximab Ineffective for Focal Segmental Glomerulosclerosis: A Long-Term Observation Study.高剂量利妥昔单抗治疗局灶节段性肾小球硬化症无效：一项长期观察研究。
Am J Nephrol. 2017;46(2):108-113. doi: 10.1159/000477944. Epub 2017 Jul 13.
10
Electron microscopic findings suggestive of focal and segmental glomerulosclerosis in patients with steroid-resistant nephrotic syndrome.电子显微镜检查结果提示激素抵抗型肾病综合征患者存在局灶节段性肾小球硬化。
Ultrastruct Pathol. 2019;43(1):6-12. doi: 10.1080/01913123.2019.1584258. Epub 2019 Mar 5.

引用本文的文献

1
The role of obinutuzumab in rituximab-refractory membranous nephropathy and minimal change disease.奥妥珠单抗在利妥昔单抗难治性膜性肾病和微小病变肾病中的作用。
Clin Kidney J. 2025 Feb 8;18(3):sfaf039. doi: 10.1093/ckj/sfaf039. eCollection 2025 Mar.
2
The efficacy and safety of rituximab with or without glucocorticoid in inducing remission of MCD with different clinical presentations in adults: a retrospective study.利妥昔单抗联合或不联合糖皮质激素诱导成人不同临床表现微小病变性肾病缓解的疗效与安全性：一项回顾性研究
Clin Kidney J. 2024 May 3;17(6):sfae139. doi: 10.1093/ckj/sfae139. eCollection 2024 Jun.
3
Primary Focal Segmental Glomerulosclerosis Plasmas Increase Lipid Droplet Formation and Perilipin-2 Expression in Human Podocytes.
原发性局灶节段性肾小球硬化症患者血浆增加人足细胞脂滴形成和脂滴包被蛋白 2 的表达。
Int J Mol Sci. 2022 Dec 22;24(1):194. doi: 10.3390/ijms24010194.
4
Rituximab Induces Complete Remission of Proteinuria in a Patient With Minimal Change Disease and No Detectable B Cells.利妥昔单抗使一名微小病变病且无可检测到的B细胞患者的蛋白尿完全缓解。
Front Immunol. 2021 Feb 8;11:586012. doi: 10.3389/fimmu.2020.586012. eCollection 2020.
5
CD80 Insights as Therapeutic Target in the Current and Future Treatment Options of Frequent-Relapse Minimal Change Disease.CD80 靶点的研究进展及其在频繁复发型微小病变肾病治疗中的应用
Biomed Res Int. 2021 Jan 6;2021:6671552. doi: 10.1155/2021/6671552. eCollection 2021.
6
PD-1 and PD-L1 Expression on Circulating Lymphocytes as a Marker of Epstein-Barr Virus Reactivation-Associated Proliferative Glomerulonephritis.循环淋巴细胞中 PD-1 和 PD-L1 的表达作为与 EBV 再激活相关的增生性肾小球肾炎的标志物。
Int J Mol Sci. 2020 Oct 27;21(21):8001. doi: 10.3390/ijms21218001.
7
Nephron Number as Predictor of Corticosteroid Response in Adult Minimal Change Disease.肾单位数量作为成人微小病变病中皮质类固醇反应的预测指标
Kidney Med. 2020 Aug 25;2(5):520-522. doi: 10.1016/j.xkme.2020.08.003. eCollection 2020 Sep-Oct.
8
TLR2 Expression on Select Lymphocyte Subsets as a New Marker in Glomerulonephritis.肾小球肾炎中作为新标志物的特定淋巴细胞亚群上的TLR2表达
J Clin Med. 2020 Feb 17;9(2):541. doi: 10.3390/jcm9020541.